MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 53,831 Shares of Gilead Sciences, Inc. $GILD

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Gilead Sciences by 5.4% during the first quarter, owning over 1 million shares valued at approximately $117.96 million.
• Several hedge funds significantly boosted their stakes in Gilead Sciences, with Activest Wealth Management increasing its position by 2,837.5%, indicating growing institutional interest in the company.
• Gilead Sciences recently announced a quarterly dividend of $0.79, which will be paid on September 29th, reflecting a dividend yield of 2.8%.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,052,760 shares of the biopharmaceutical company's stock after purchasing an additional 53,831 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.08% of Gilead Sciences worth $117,961,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nissay Asset Management Corp Japan ADV increased its position in shares of Gilead Sciences by 5.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after acquiring an additional 14,009 shares during the last quarter. Golden State Wealth Management LLC increased its position in shares of Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after acquiring an additional 109 shares during the last quarter. Ariel Investments LLC increased its position in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock valued at $48,229,000 after acquiring an additional 30,630 shares during the last quarter. Mufg Securities Americas Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $1,699,000. Finally, ASR Vermogensbeheer N.V. acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $11,688,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of GILD stock traded down $0.53 during trading on Wednesday, hitting $115.24. The company had a trading volume of 1,828,025 shares, compared to its average volume of 8,099,666. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market capitalization of $142.98 billion, a P/E ratio of 22.96, a price-to-earnings-growth ratio of 0.79 and a beta of 0.36. The stock's 50-day moving average price is $113.77 and its 200 day moving average price is $109.99. Gilead Sciences, Inc. has a one year low of $79.64 and a one year high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is 62.95%.

Insider Buying and Selling

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 82,000 shares of company stock valued at $9,371,330. 0.27% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on GILD shares. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Royal Bank Of Canada boosted their price target on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Finally, Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.